Skip to content

Comparison of topical skin adhesive for skin closure in ankle fracture

Comparison of 2-octyl cyanoacrylate and n-butyl cyanoacrylate topical skin adhesive for skin closure in ankle fracture, a prospective randomized trial)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CRIS
Registry ID
KCT0006476
Enrollment
56
Registered
2021-08-20
Start date
2018-04-05
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : According to the assigned group, 2-octyl cyanoacrylate TSA (Dermabond® Prineo®, Ethicon, Somerville, NJ) or n-butyl cyanoacrylate TSA (LiquiBand®, Advanced Medical Solutions, Winsford

Sponsors

Koera University Guro Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who required open reduction and plate fixation for the isolated lateral malleolar fracture will be included. Among the patients with rotational ankle fractures, those who are combined with a posterior malleolar fracture or a partial deltoid ligament rupture but only required open reduction and plate fixation for the lateral malleolar fracture will be also included.

Exclusion criteria

Exclusion criteria: (1) under 18 or over 65 years of age, (2) history of previous surgery at the ankle joint, (3) significant medical comorbidity that could potentially affect wound healing (e.g., end-stage renal failure, peripheral vascular disease), (4) history of keloid formation, open fracture, or other notable skin injuries around the ankle joint combined with fracture.

Design outcomes

Primary

MeasureTime frame
Hollander Wound Evaluation Scale (HWES)

Secondary

MeasureTime frame
Visual Analog Scale and 5-item Likert scale to assess patient satisfaction to wound cosmesis.

Countries

Korea, Republic of

Contacts

Public ContactYoung Hwan Park

Koera University Guro Hospital

ospark1982@gmail.com+82-2-2626-3084

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026